RCMNY
KRYS icon

Rubric Capital Management (New York)’s Krystal Biotech KRYS Stock Holding History

Rubric Capital Management (New York)’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-92,609
Closed -$7.34M – 83
2022
Q4 		$7.34M Hold
92,609
– – 0.32% 66
2022
Q3 		$6.46M Hold
92,609
– – 0.33% 60
2022
Q2 		$6.08M Buy
+92,609
New +$5.76M 0.32% 56

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Rubric Capital Management (New York)'s KRYS Position: Q1 2023 in Review

Rubric Capital Management (New York) sold out of Krystal Biotech (KRYS) in Q1 2023, closing a stake of 92,609 shares — an estimated $7.34M sold.

Rubric Capital Management (New York) first reported a position in KRYS in Q2 2022 and held it in 3 quarters. The position peaked at $7.34M in Q4 2022. 160 funds tracked by Wall St. Rank hold KRYS as of Q1 2023.

  • Rubric Capital Management (New York) reported no remaining Krystal Biotech position as of Q1 2023 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 92,609 Krystal Biotech shares in Q1 2023, an estimated $7.34M.
  • Rubric Capital Management (New York) first reported a position in Krystal Biotech in Q2 2022 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Krystal Biotech position peaked at $7.34M in Q4 2022.
  • 160 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2023, filed 12 May 2023.